The reduced release of GH by GHRH in 8 subjects aged 65-69 years is augmented considerably by rivastigmine, a drug for Alzheimer's disease

Gerontology

Volumn 49, Issue 3, 2003, Pages 191-195

  Obermayr, Rudolf P ^a,c   Mayerhofer, Lothar ^a   Knechtelsdorfer, Maarten ^a   Tragl, Karl Heinz ^a   Geyer, Georg ^b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c First Medical Department   (Austria)

Author keywords

Growth hormone; Growth hormone releasing hormone; Repeated GHRH test; Rivastigmine; Somatopause

Indexed keywords

BRAIN ENZYME; CHOLINESTERASE INHIBITOR; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BOLUS INJECTION; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; GERIATRIC DISORDER; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SOMATOPAUSE; STATISTICAL ANALYSIS;

AGED; ALZHEIMER DISEASE; CARBAMATES; CHOLINESTERASE INHIBITORS; FEMALE; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MALE; PHENYLCARBAMATES;

EID: 0037268983     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069175     Document Type: Article

References (43)

1. Prinz PN, Weitzman ED, Cunningham GR, Karacan I: Plasma growth hormone during sleep in young and aged men. J Gerontol 1983; 38:519-524.
2. Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, Furlanetto R, Rogol AD, Kaiser DL, Thorner MO: Effects of sex and age on 24-hour profile of growth hormone secretion in man: Importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51-58.
3. Kelijman M: Age-related alterations of the growth hormone/insulin-like growth factor I axis. J Am Geriatr Soc 1991;39:295-307.
4. Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA, Brain RP: Impaired growth hormone secretion in the adult population: Relation to age and adiposity. J Clin Invest 1981; 67:1361-1369.
5. Vermeulen A: Nyctohemeral growth hormone profiles in young and aged men: Correlation with somatomedin-C levels. J Clin Endocrinol Metab 1987;64:884-888.
6. Iranmanesh A, Lizarralde G, Verdhuis JD: Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991;73:1081-1088.
7. Florini JR, Prinz PN, Vitiello MV, Hintz RL: Somatomedin-C levels in healthy young and old men: Relationship to peak and 24-hour integrated levels of growth hormone. J Gerontol 1985;40:2-7.
8. Russel-Aulet M, Jaffe CA, Demott-Friberg R, Barkan AL: In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: Evidence for relative GHRH deficiency in aging. J Clin Endocrinol Metab 1999;84:3490-3497.
9. Bengtsson BA, Johansson G, Shalet SM, Simpson H, Sonsken PH: Treatment of growth hormone deficiency in adults. J Clin Endocrinol Metab 2000;85:933-942.
10. Vance ML, Mauras N: Growth hormone therapy in adults and children. N Engl J Med 1999; 341:1206-1216.
11. Martin F: Frailty and the somatopause. Growth Horm IGF Res 1999;9:3-10.
12. Sonsken P: Growth hormone and the somatopause. Growth Horm IGF Res 1999;9:1-2.
13. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE: Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
14. Martin FC, Yeo AL, Sonsken PH: Growth hormone secretion in the elderly: Ageing and the somatopause. Baillières Clin Endocrinol Metab 1997;11:223-250.
15. Aleman A, Verhaar HJ, De Haan EH, De Vries WR, Samson MM, Drent ML, Van der Veen EA, Koppeschaar HP: Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab 1999;84:471-475.
16. Seshadri S, Beiser A, Selhub J, Jacques PR, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
17. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A: Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: A randomized controlled trial. J Clin Endocrinol Metab 2001;86:1518-1524.
18. Friend K, Iranmanesh A, Login IS, Veldhuis JD: Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release. Eur J Endocrinol 1997;137:377-386.
19. Giustina A, Bossoni S, Bodoni C, Doga M, Girelli A, Buffoli MG, Schettino M, Wehrenberg WB: The role of cholinergic tone in modulating the growth hormone response to growth hormone releasing hormone in normal man. Metabolism 1991;40:519-523.
20. Mazza E, Ghigo E, Goffi S, Procopio M, Im-periale E, Arvat E, Bellone J, Boghen MF, Müller EE, Camanni F: Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone. J Endocrinol Invest 1989;12:795-798.
21. Coiro V, Volpi R, Bertoni P, Finzi G, Marcato A, Caiazza A, Colla R, Giacalone G, Rossi G, Chiodera P: Effect of potentiation of cholinergic tone by pyridostigmine on the GH response to GHRH in elderly men. Gerontology 1992; 38:217-222.
22. Massara F, Ghigo E, Molinatti P, Mazza E, Locatelli V, Müller EE, Camanni F: Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man. Acta Endocrinol (Copenh) 1986; 113:12-16.
23. Penalva A, Muruais C, Casanueva FF, Dieguez C: Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone releasing hormone induced GH secretion in normal subjects. J Clin Endocrinol Metab 1990; 70:324-329.
24. Arvat E, Cappa M, Casanueva FF, Dieguez C, Ghigo E, Nicolosi M, Valcavi R, Zini M: Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women. J Clin Endocrinol Metab 1993;76:374-377.
25. Ghigo E, Goffi S, Arvat E, Nicolosi M, Procopio M, Bellone J, Imperiale E, Mazza E, Baracchi G, Camanni F: Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging. Acta Endocrinol (Copenh) 1990; 123:169-173.
26. Kennedy JS, Polinsky RJ, Johnson B, Loosen P, Enz A, Laplanche R, Schmidt D, Mancione LC, Parris WC, Ebert MH: Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol 1999;19:513-521.
27. Hoeck HC, Jakobsen PE, Vestergaard P, Falhof J, Laurberg P: Differences in the reproducibility and peak growth hormone responses to repeated testing with various stimulators in healthy adults. Growth Horm IGF Res 1999;9: 18-24.
28. Sartorio A, Spada A, Morabito F, Fagla G: Different GH responsiveness to repeated GHRH administration in normal children and adults. J Endocrinol Invest 1988;11:727-729.
29. Sartorio A, Conti A, Ferrero S, Spada A, Faglia G: GH responsiveness to repeated GHRH or hexarelin administration in normal adults. J Endocrinol Invest 1995;18:718-722.
30. 2 in rat anterior pituitary cells in culture. Mol Cell Endocrinol 1986; 46:79-89.
31. Polinsky RJ: Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998;20:634-647.
32. Spencer CM, Noble S: Rivastigmine: A review of its use in Alzheimer's disease. Drugs Aging 1998;13:391-411.
33. Jann MW: Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 2000; 20:1-12.
34. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N: Clinical and cost-effectiveness of donepezil. rivastigmine and galantamine for Alzheimer's disease: A rapid and systematic review. Health Technol Assess 2001;5:1-137.
35. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999;318:633-638.
36. Potki SG, Anand R, Hartman R, Veach J, Grossberg G: Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:713-720.
37. Lai Z, Roos P, Zhai O, Olsson Y, Fholenhag K, Larsson C, Nyberg F: Age-related reduction of human growth hormone-binding sites in the human brain. Brain Res 1993;621:260-266.
38. Nyberg F: Aging effects on growth hormone receptor binding in the brain. Exp Gerontol 1997;32:521-528.
39. Squire LR: Memory and the hippocampus: A synthesis from findings with rats, monkeys, and humans. Psychol Rev 1992;99:195-231.
40. Schneider-Rivas S, Rivas-Arancibia S, Vazquez-Pereyra F, Vazquez-Sandoval R, Borgonio-Pérez G: Modulation of long-term memory and extinction responses induced by growth hormone (GH) and growth hormone releasing hormone (GHRH) in rats. Life Sci 1995;56: PL433-PL441.
41. Aleman A, Verhaar HJ, De Haan EH, De Vries WR, Samson MM, Drent ML, Van der Veen EA, Koppeschaar HP: Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab 1999;84:471-475.
42. Deijen JB, De Boer H, Van der Veen EA: Cognitive changes during growth hormone replacement in adult men. Psychoneuroendocrinology 1998;23:45-55.
43. Mayeux R, Sano M: Treatment of Alzheimer's disease. N Engl J Med 1999;341:1670-1679.